학술논문
Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVExtend trial
Document Type
Report
Author
Source
Mayo Clinic Proceedings. February, 2017, Vol. 92 Issue 2, p200, 11 p.
Subject
Language
English
ISSN
0025-6196
Abstract
Objective: To assess the efficacy and safety of 18 months of subcutaneous abaloparatide (ABL-SC) or placebo (PBO) followed by 6 months of alendronate (ALN) (preplanned interim analysis). Patients and Methods: [...]